Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with mFOLFOX6 in Locally Advanced Colon Cancer
NCT04625803Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in colon cancer, sponsored by Zhejiang University. Started Jan 2021; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04625803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625803.